MOA Peptide substrate competitive inhibitor;SAM noncompetitive inhibitor

DESCRIPTION UNCO0642 is compound 7 in . This is a compound from the Structural Genomics Consortium's (SGC) Epigenetics Probes Collection. (GtoPdb)

COMMENT UNC0642 potently and specifically inhibits G9a and GLP compared with a wide range of pharmacologically important proteins (except for the histamine H3 receptor) in cell-free assays. Importantly, the compound shows clear concentration differences between the cellular functional activity (on-target activity) and cytotoxic activity (approximately three orders of magnitude). Therefore, chemical scaffold-induced, non-specific cellular effects would be avoided when the compound is used at the concentrations ranging from 100 nM to 1 microM. The roughly obtained PK values seem acceptable for in vivo mouse studies; however, whether i.p. administration of UNC0642 modulates the pharmacodynamics of the target (assayed by looking at levels of H3H9me2 in major tissues) would be worthwhile to examine before in vivo applications are pursued. Sep 7 2016 - 8:01am; The in vitro potency and selectivity against other family members is good. The margin between concentrations that yield a functional effect and cellular toxicity was determined and is at least 80-fold. Limited PK data are provided in the original paper; however, dosing is limited to IP administration, and only Cmax and AUC(0-24hr) are reported. Plasma Cmax at this dose is 1.7 uM. In the absence of protein-binding data at this concentration, relative in vitro potency cannot be estimated, and direct pharmacodynamic data for in vivo target modulation are absent. A second publication (doi:10.1038/nm.4257) reports the in vivo use of this compound using the same dosing regimen, and it shows modulation of maternally repressed gene expression consistent with the in vitro cellular data. Direct demonstration of histone methylation modulation in vivo would increase my confidence in the mechanism of action of this probe. Jan 23 2017 - 1:25pm; This is a well characterised probe with dual activity against the related targets GLP and G9a. The probe has been evaluated for selectivity against a variety of off-targets including kinases, GPCRs, etc. and appears to be suitably selective. Moreover, selectivity against other related epigenetic targets has also been undertaken and appears satisfactory. Reversibility, cellular activity, etc. are well described and some in vivo data support the use of the probe in model organisms. However, it is worth noting that the probe is recommended for IP dosing only. Jun 19 2017 - 12:54pm

DESCRIPTION UNC0642 is a potent and selective lysine methyltransferases G9a and GLP inhibitor, with an IC50 of <2.5 nM for G9a.

PRICE 139

MOA Inhibitor (Chemical Probes.org)

DESCRIPTION Glucokinase activator (Tocris Bioactive Compound Library)

DESCRIPTION Potent and selective G9a and GLP inhibitor (Tocriscreen Plus)

DESCRIPTION UNC0642 is an effective and specific G9a/GLP inhibitor (IC50< 2.5 nM). (TargetMol Bioactive Compound Library)